NanoVation Therapeutics
Business Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2405 Wesbrook Mall Fl 4, Vancouver, Brit...Website
www.nanovationtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About NanoVation Therapeutics
NanoVation Therapeutics specializes in the development of scalable, nucleic acid-agnostic lipid nanoparticle (LNP) formulations tailored for specific targets, payloads, and routes of administration. Their innovative long-circulating LNP (lcLNP) technology enables the effective delivery of genetic medicines beyond the liver, enhancing potency, safety, and stability. The company collaborates with partners to overcome barriers in genetic medicine, providing customized solutions and a comprehensive delivery toolbox. With a multidisciplinary team of experts, NanoVation aims to accelerate the development of next-generation therapies for various diseases.Explore more
NanoVation Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NanoVation Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if NanoVation Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if NanoVation Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once NanoVation Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
NanoVation Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on NanoVation Therapeutics recently announced quarterly report
Click to see if NanoVation Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at NanoVation Therapeutics
Product Launch: Get notified when NanoVation Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to NanoVation Therapeutics
Compare insights from companies similar to NanoVation Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NanoVation Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NanoVation Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NanoVation Therapeutics.
NanoVation Therapeutics Tech Stack
A closer look at the technologies used by NanoVation Therapeutics
See more technologies
Most Recent Scoops
Hiring Plans
NanoVation Therapeutics has more open roles in Sales than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Funding
Funding
Open Position
Open Position
NanoVation Therapeutics News & Media
NanoVation Therapeutics Announces Expansion of Board of Directors and Completion of Funding Round Led by Convergent Ventures
VANCOUVER, British Columbia--(BUSINESS WIRE)--NanoVation Therapeutics, a platform company developing innovative technologies to overcome barriers to nucleic acid delivery, today announced the expansion of its Board of Directors and the close of a funding round led by Convergent Ventures. These two developments preceded NanoVation’s September announcement of an up to US$600 million multi-year partnership with Novo Nordisk to advance the development of novel genetic medicines targeting cardiometaNanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases
VANCOUVER, British Columbia--(BUSINESS WIRE)--NanoVation Therapeutics, a platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, today announced a multi-year partnership with Novo Nordisk to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The partnership combines NanoVation Therapeutics’ proprietary long-circulating lipid nanoparticle (lcLNP™) technology for RNA delivery to cells outside of the liverParticle Works Partners With Nanovation Therapeutics UK For Lipid Nanoparticle Development
CAMBRIDGESHIRE, UK, February 23, 2023 /EINPresswire.com/ -- Particle Works, a leading provider of game-changing microfluidic nanoparticle synthesis platforms, is collaborating with NanoVation Therapeutics UK to reduce the time and costs associated with …
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding NanoVation Therapeutics
Sign Up For FreeTo access detailed company insights
NanoVation Therapeutics specializes in the development of scalable, nucleic acid-agnostic lipid nanoparticle (LNP) formulations tailored for specific targets, payloads, and routes of administration. Their innovative long-circulating LNP (lcLNP) technology enables the effective delivery of genetic medicines beyond the liver, enhancing potency, safet... Read More
